01801.HK
Innovent Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 102.40
−0.19%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 27.0B | 13.0B | 9.4B | 6.2B | 4.6B |
| Cost of Revenue | 5.7B | 3.0B | 1.5B | 1.8B | 931.0M |
| Gross Profit | 21.3B | 10.0B | 7.9B | 4.4B | 3.6B |
| Operating Expenses | |||||
| R&D Expense | 5.6B | 2.6B | 2.7B | 2.2B | 2.9B |
| SG&A Expense | 13.2B | 6.6B | 5.1B | 3.9B | 3.4B |
| General & Admin Expense | 1.3B | 927.0M | 738.0M | 750.3M | 835.5M |
| Selling & Marketing Expense | 8.2B | 5.7B | 4.3B | 3.1B | 2.6B |
| Other Expenses | — | — | (112.5M) | — | (90.2M) |
| Total Operating Expenses | 18.8B | 9.3B | 7.7B | 6.1B | 6.2B |
| Cost and Expenses | 24.4B | 12.3B | 9.2B | 7.9B | 7.7B |
| Operating Income (EBIT) | 2.6B | 733.6M | (755.9M) | (1.7B) | (3.1B) |
| Non-Operating | |||||
| Interest Income | 874.3M | 427.3M | 423.5M | 452.8M | 189.5M |
| Interest Expense | 58.4M | 77.5M | 67.6M | 98.6M | 101.7M |
| Net Interest Income | 815.9M | 349.8M | 355.8M | 354.2M | 87.8M |
| Other Non-Op Income/Expense | 142.0M | 105.3M | (336.7M) | 534.9M | 952.4M |
| Non-Operating Income (excl Interest) | 308.4M | — | 269.1M | (633.5M) | (513.1M) |
| EBT (Pre-Tax Income) | 2.7B | 838.9M | (78.6M) | (1.1B) | (2.2B) |
| Income Tax Expense | 394.9M | 25.4M | 16.0M | (116.5M) | 8.8M |
| Bottom Line | |||||
| Net Income | 2.3B | 813.6M | (94.6M) | (1.0B) | (2.2B) |
| Earnings from Cont. Ops | 2.3B | 813.6M | (94.6M) | (1.0B) | (2.2B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 2.3B | 813.6M | (94.6M) | (1.0B) | (2.2B) |
| Per Share | |||||
| Basic EPS | HK$1.38 | HK$0.48 | (HK$0.06) | (HK$0.66) | (HK$1.46) |
| Diluted EPS | HK$1.34 | HK$0.47 | (HK$0.06) | (HK$0.66) | (HK$1.46) |
| Revenue Per Share | HK$15.65 | HK$7.53 | HK$5.79 | HK$3.98 | HK$3.06 |
| Shares | |||||
| Basic Shares Outstanding | 1.7B | 1.7B | 1.6B | 1.6B | 1.5B |
| Diluted Shares Outstanding | 1.8B | 1.7B | 1.6B | 1.6B | 1.5B |
| Profitability Metrics | |||||
| EBITDA | 3.3B | 1.3B | (480.3M) | (660.7M) | (1.7B) |
| D&A | 995.8M | 576.5M | 275.6M | 385.1M | 319.4M |
| EBIT | 2.3B | 733.6M | (755.9M) | (1.0B) | (2.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026